In a South Indian study, an 'in-house' enzyme-linked immunosorbent assay (ELISA) was developed to evaluate the potential of herpes simplex virus (HSV)-specific tear secretory IgA (sIgA) in the diagnosis of herpes simplex keratitis (HSK). The presence of HSV-specific tear sIgA was found to be diagnostic in 20.28% of cases. The usefulness of the sIgA ELISA system was evaluated against HSV isolation, which is the 'gold standard' and HSV antigen detection, a more sensitive, commonly employed method. Analysis of HSV-specific IgG and IgM results showed their failure as reliable indicators of active or ongoing infection. Comparison of sIgA ELISA with culture as 'gold standard' showed its sensitivity, specificity, and positive and negative predictive values to be 60% (95% CI 36.4-80), 93.2% (95% CI 86.7-96.8), 60% (95% CI 36.4-80), and 93.2% (95% CI 86.7-96. 8), respectively. This study is the first report on the complete evaluation of the usefulness of tear anti-HSV sIgA in the laboratory diagnosis of HSK, taking into account both epithelial and stromal keratitis cases.
SLE is a multiorgan autoimmune disease that affects women of childbearing age. The incidence and prevalence of SLE in pregnancy are 1.4-21.9 and 7.4-159.4 per 100,000 people, respectively. 1 It is first diagnosed during pregnancy in 10-30% of the cases. Women with lupus nephritis have a good pregnancy outcome if the disease remains in remission. 2 Active nephritis is associated with higher incidence of maternal complications compared with women without nephritis. 3 Foetal death with active maternal nephritis also increased than in those with quiescent nephritis. Renal involvement in SLE may either be in the form of active lupus nephritis at the time of conception or a new-onset LN or a lupus flare, all have potential maternal, perinatal morbidity and mortality. Here a case of pregnancy with active lupus nephritis of new onset had a good maternal and foetal outcome is reported. KEYWORDSLupus nephritis, Systemic Lupus Erythematosus, Proteinuria, IUGR. INTRODUCTION 26 years old primi with 33 weeks gestation presented to our OPD with a history of swelling of both legs of 2 months and skin rashes over the face, abdomen, both legs, breasts, and skin over the back of 15 days duration. There was no history of headache, vomiting, or decreased urine output. She was booked at a private hospital and at 20 weeks all routine investigations were done including GCT was within normal limits. Target USG was done at 22 weeks and 6 days and congenital anomalies ruled out. She was a known case of hypothyroidism on regular treatment. TSH in first trimester was 6.7 and was put on T. Thyroxine 100 microgram. At 24 weeks, she developed swelling of both legs and skin rashes and at 32 weeks skin lesions were erythematous with crusting and scaling and were not itchy started in the breasts, anterior abdominal wall, anterior chest wall, both legs, and lastly involved the face. It was in the malar region over the face. History of fever, insect bite, and recent drug intake were ruled out. There was no history of joint pain. There was no past history suggestive of any connective tissue disorder. All relevant investigations done and preeclampsia ruled out. The above-mentioned presenting complaints of the patient were suspicious of connective tissue disorder. A thorough clinical examination and relevant investigation were done. The diagnosis of active lupus nephritis of new onset was made as per American College of Rheumatology criteria. HOW TO CITE THIS ARTICLE:
We report the case of young primiparous women with transient ischaemic attack diagnosed as primary antiphospholipid antibody syndrome. Lupus anticoagulant and anticardiolipin antibodies were elevated. There was no clinical or laboratory evidence for other autoimmune or systemic illnesses. We are presenting the case due to the rarity of the same.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.